Neoadjuvant Chemo Plus Immunotherapy in Resectable NSCLC

(MedPage Today) -- At the recent American Society of Clinical Oncology (ASCO) annual meeting, updated data were presented on the CheckMate 816 trial, a phase III study looking at the efficacy and safety of adding the immune checkpoint inhibitor...